Search results for "endpoint"

showing 10 items of 437 documents

NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke

2019

Background and Purpose— Ischemic stroke causes major disability as a consequence of neuronal loss and recurrent ischemic events. Biomarkers predicting tissue damage or stroke recurrence might be useful to guide an individualized stroke therapy. NfL (neurofilament light chain) is a promising biomarker that might be used for this purpose. Methods— We used individual data of patients with an acute ischemic stroke and clinical long term follow-up. Serum NfL (sNfL) was quantified within 24 hours after admission and after 1 year and compared with other biomarkers (GDF15 [growth differentiation factor 15], S100, NT-proBNP [N-terminal pro-B-type natriuretic peptide], ANP [atrial natriuretic peptid…

Advanced and Specialized Nursing0303 health sciencesmedicine.medical_specialtybusiness.industrymedicine.drug_classOdds ratiomedicine.disease3. Good healthBrain ischemia03 medical and health sciences0302 clinical medicineInterquartile rangeModified Rankin ScaleInternal medicineDiabetes mellitusClinical endpointmedicineNatriuretic peptideCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke030217 neurology & neurosurgery030304 developmental biologyStroke
researchProduct

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

2006

OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by atorvastatin 10 mg/day in patients with stable coronary heart disease (CHD). The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes. RESEARCH DESIGN AND METHODS—A total of 1,501 patients with diabetes and CHD, with LDL cholesterol levels of <130 mg/dl, were randomized to double-blind therapy with either atorvastatin 10 (n = 753) or 80 (n = 748) mg/day. Patients were followed for a median of 4.9 years…

Advanced and Specialized Nursingmedicine.medical_specialtyCholesterolbusiness.industryEndocrinology Diabetes and MetabolismAtorvastatinHazard ratiomedicine.diseasechemistry.chemical_compoundEndocrinologyBlood pressurechemistryInternal medicineDiabetes mellitusInternal MedicineClinical endpointCardiologyMedicinelipids (amino acids peptides and proteins)cardiovascular diseasesMyocardial infarctionAdverse effectbusinessmedicine.drugDiabetes Care
researchProduct

Diagonal ear lobe crease and atherosclerosis : a review of the medical literature and dental implications

2011

In Spain a significant number of individuals die from atherosclerotic disease of the coronary and carotid arteries without having classic risk factors and prodromal symptoms. The diagonal ear lobe crease (DELC) has been characterized in the medical literature as a surrogate marker which can identify high risk patients having occult atherosclerosis. This topic however has not been examined in either the medical or dental literature emanating from Spain. The majority of clinical, angiography and postmortem reports support the premise that DELC is a valuable extravascular physical sign able to distinguish some patients at risk of succumbing to atherosclerosis of the coronary arteries. A minori…

AgingArteriosclerosisGerodontologypanoramic radiographsCoronary Artery DiseaseCardiovascularCoronary artery diseaseCoronary diseasesatherosclerosis diseaseEar Externalmedicine.diagnostic_testStomatognathic DiseasesEar:CIENCIAS MÉDICAS [UNESCO]Heart Diseasemedicine.anatomical_structureOrellaUNESCO::CIENCIAS MÉDICASRadiologyRadiologia dentalcalcified carotid arterymedicine.medical_specialtyPanoramic radiographVital signsArteriosclerosiMalalties coronàriesPanoramicRadiography PanoramicDiagonal ear lobe creasemedicineotorhinolaryngologic diseasesHumansMedical historyEspanyaDental/Oral and Craniofacial DiseaseGeneral DentistryHeart Disease - Coronary Heart DiseaseSurrogate endpointbusiness.industryPreventionReview-ArticleDental radiologyatheromasAtherosclerosismedicine.diseaseOccultExternalRadiographyCoronary arteriesArterioesclerosiOtorhinolaryngologySpainDentistryAngiographySurgerybusiness
researchProduct

Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?

2019

Direct-acting antivirals (DAAs) revolutionised the treatment of chronic HCV-related disease achieving high rates of sustained virological response (SVR), also in more advanced patients, with a good safety profile and a proven positive effect on the reduction of risk of HCC occurrence. Nevertheless, patients with an history of successfully treated early HCC were initially excluded from pivotal trials. Although some initial retrospective studies, affected by several methodological issues, raised concerns regarding a possible harmful effect on the risk of HCC recurrence after antiviral therapy, more recent prospective studies and meta-analyses provided evidence that risk of HCC recurrence afte…

Antiviral AgentSurvival RateCarcinoma HepatocellularRisk FactorsEndpoint DeterminationLiver NeoplasmResearch DesignRisk FactorLiver NeoplasmsHumansHepatitis C ChronicAntiviral AgentsHuman
researchProduct

A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aorti…

2016

Aims Our aim was to assess the clinical outcomes of the Direct Flow Medical Transcatheter Aortic Valve System (DFM-TAVS), when used in routine clinical practice. Methods and results This is a prospective, open-label, multicentre, post-market registry of patients treated with DFM-TAVS according to approved commercial indications. Echocardiographic and angiographic data were evaluated by an independent core laboratory and adverse events were adjudicated and classified according to VARC-2 criteria by an independent clinical events committee. The primary endpoint was freedom from all-cause mortality at 30 days post procedure. Secondary endpoints included procedural, early safety and efficacy en…

Aortic valveMalemedicine.medical_specialtyCardiac Catheterizationmedicine.medical_treatmentAortic Valve InsufficiencyRegurgitation (circulation)030204 cardiovascular system & hematologyTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineClinical endpointHumans030212 general & internal medicineHeart valveProspective StudiesRegistriesCardiac catheterizationAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industryAortic Valve Stenosismedicine.disease3. Good healthClinical trialStenosismedicine.anatomical_structureTreatment OutcomeAortic valve stenosisAortic ValveHeart Valve ProsthesisCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

The role of minimal access valve surgery in the elderly. A meta-analysis of observational studies

2016

Background Minimal access valve surgery, both mitral and aortic, may be related to improvement in specific post-operative outcomes, therefore may be beneficial for the subgroup of the elderly referred for valve surgery. Methods A systematic literature review identified several different studies, of which 6 fulfilled criteria for meta-analysis. Outcomes for a total of 1347 patients (675 conventional standard sternotomy and 672 minimally invasive valve surgery) were assessed with a meta-analysis using random effects modeling. Heterogeneity, subgroup analysis with quality scoring were also assessed. The primary endpoint was early mortality. Secondary endpoints included intra and post-operative…

Aortic valvemedicine.medical_specialtymedicine.medical_treatmentSubgroup analysisContext (language use)030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineMinimally invasive surgerylawMitral valvemedicineClinical endpointCardiopulmonary bypassHumansMinimally Invasive Surgical ProceduresIntubationMeta-analysiAortic valve; Meta-analysis; Minimally invasive surgery; Mitral valve; Statistics; SurgeryCardiac Surgical ProceduresStatisticAgedAged 80 and overCardiopulmonary BypassModels Statisticalbusiness.industryAge FactorsGeneral MedicineSurgeryObservational Studies as TopicTreatment Outcomemedicine.anatomical_structure030228 respiratory systemAortic ValveMeta-analysisAnesthesiaMitral ValveSurgerybusinessInternational Journal of Surgery
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes.

2017

Background: Information about the impact of frailty in patients with acute coronary syndromes (ACS) is scarce. No study has assessed the prognostic impact of frailty as measured by the FRAIL scale in very elderly patients with ACS. Methods: The prospective multicenter LONGEVO-SCA registry included unselected patients with ACS aged 80 years or older. A comprehensive geriatric assessment was performed during hospitalization, including frailty assessment by the FRAIL scale. The primary endpoint was mortality at 6 months. Results: A total of 532 patients were included. Mean age was 84.3 years, 61.7% male. Most patients had positive troponin levels (84%) and high GRACE risk score values (mean 16…

Background informationMalemedicine.medical_specialtyTime FactorsFrail ElderlyEnfermedad cardiovascularAncianoComorbidityKaplan-Meier Estimate030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineInternal medicineCause of DeathClinical endpointPrevalenceMedicineHumansIn patient030212 general & internal medicineProspective StudiesRegistriesAcute Coronary SyndromeGeneral NursingProportional Hazards ModelsAged 80 and overFramingham Risk ScoreEjection fractionbiologyFrailtybusiness.industryHealth PolicyMortality rateGeriatric assessmentGeneral MedicinePrognosisTroponinSurvival AnalysisSpainbiology.proteinCardiopatía coronariaFemaleGeriatrics and GerontologybusinessAncianosJournal of the American Medical Directors Association
researchProduct

Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent.

2014

Bare metal stents (BMS) have similar rates of death and myocardial infarction (MI) compared to drug-eluting stents (DES). DES lower repeat revascularization rates compared to BMS, but may have higher rates of late stent thrombosis (ST) potentially due to impaired endothelialization requiring longer dual anti-platelet therapy (DAPT). OMEGA evaluated a novel BMS designed to have improved deliverability and radiopacity, in comparison to currently available platforms.OMEGA was a prospective, multicenter, single-arm study enrolling 328 patients at 37 sites (US and Europe). Patients received the OMEGA stent (bare platinum chromium element stent) for the treatment of de novo native coronary artery…

Bare-metal stentTarget lesionChromiumMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentRevascularizationCoronary AngiographyProsthesis DesignRisk AssessmentSeverity of Illness IndexCoronary artery diseaseCoronary RestenosisInternal medicineClinical endpointMedicineHumansSingle-Blind MethodMyocardial infarctionProspective StudiesAngioplasty Balloon CoronaryAgedPlatinumAged 80 and overbusiness.industryCoronary StenosisStentGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureTreatment OutcomeMetalsCardiologyFemaleStentsPatient SafetyCardiology and Cardiovascular MedicinebusinessArteryFollow-Up StudiesCardiovascular revascularization medicine : including molecular interventions
researchProduct

ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R)…

2021

Context Tafasitamab+LEN, a chemotherapy-free, novel treatment for R/R DLBCL, demonstrated efficacy in ASCT-ineligible patients in the single-arm Phase II L-MIND study (NCT02399085). Objective To compare outcomes in patients treated with tafasitamab+LEN in the L-MIND study with matched patient populations treated with commonly administered NCCN-/ESMO-recommended therapies for non-transplant-eligible patients with R/R DLBCL in routine clinical practice. Design RE-MIND2 (NCT04150328) is an observational, retrospective cohort study. The L-MIND tafasitamab+LEN cohort was matched with RE-MIND2 patients using estimated propensity score-based 1:1 nearest neighbor matching balanced for nine patient …

BendamustineOncologyCancer Researchmedicine.medical_specialtybusiness.industryContext (language use)Retrospective cohort studyHematologymedicine.diseaseOncologyInternal medicineCohortmedicineClinical endpointRituximabbusinessDiffuse large B-cell lymphomamedicine.drugLenalidomideClinical Lymphoma Myeloma and Leukemia
researchProduct